That's the rumor. I hope it's right. I'm guessing it will be less money up front [maybe $100 million] and more money if it works later down the road. It's all a guess. But I like the price move up on 4+ million shares. If we can get more on Monday, just maybe something good is up. Below is some of the the rumor on Yahoo message broad.
I believe there is substantial interest in hESC's from USA, Swiss and Chinesse companies. Properly, GERN is focusing on cancer treatments now, but their eventual gain from hESC's could be much greater than $300 million. The speculation is great, and the outcome may be a pleasant surprise on several fronts.
Cancer is Geron's main interest now, but there is still behind the scenes collaboration with GE, and discussions with other companies. GE has the deep pockets that GERN needs. I believe the agreement extends to cancer research, but hESC's are still in the picture. This stock is a speculation, with many "irons in the fire".
---------------------------------------------
Part of GE agreement:
"Under the agreement between GE and Geron, Geron will provide the hESCs to GE who will develop and commercialize lab equipment that facilitates the use of the hESCs in drug development and toxicity screening. The lab equipment will then be marketed to pharmaceutical companies and research labs. According to Konstantin Fiedler, general manager of cell technologies at GE’s Healthcare division, the market for toxicity testing is expected to be in the hundreds of millions of dollars by 2020, from which Geron will begin receiving royalties by 2010.
Scientists from both companies will collaborate in the venture, with GE Healthcare providing all R&D funding. According to David Earp, senior vice president for business development and chief patents counsel at Geron, "We had an asset that we were not able to exploit fully." According to Konstantin Fiedler, general manager of cell technologies at GE Healthcare, "This agreement marks a further step in GE Healthcare’s cell technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and therapy markets."
Cancer is Geron's main interest now, but there is still behind the scenes collaboration with GE, and discussions with other companies. GE has the deep pockets that GERN needs. I believe the agreement extends to cancer research, but hESC's are still in the picture. This stock is a speculation, with many "irons in the fire".
---------------------------------------------
Part of GE agreement:
"Under the agreement between GE and Geron, Geron will provide the hESCs to GE who will develop and commercialize lab equipment that facilitates the use of the hESCs in drug development and toxicity screening. The lab equipment will then be marketed to pharmaceutical companies and research labs. According to Konstantin Fiedler, general manager of cell technologies at GE’s Healthcare division, the market for toxicity testing is expected to be in the hundreds of millions of dollars by 2020, from which Geron will begin receiving royalties by 2010.
Scientists from both companies will collaborate in the venture, with GE Healthcare providing all R&D funding. According to David Earp, senior vice president for business development and chief patents counsel at Geron, "We had an asset that we were not able to exploit fully." According to Konstantin Fiedler, general manager of cell technologies at GE Healthcare, "This agreement marks a further step in GE Healthcare’s cell technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and therapy markets."
No comments:
Post a Comment